nktr-214
Recombinant proteinexperimental
Clinical trial activity
11 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02869295)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Ependymoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Medulloblastoma · Phase 1/Phase 2
- Melanoma · Phase 3
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuroblastoma · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Rhabdomyosarcoma · Phase 1/Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 3
Mechanism of action
- Interleukin-2 receptor beta chainACTIVATOR
IL2RB activator
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nktr-214
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04936841 | Phase 2 | Aug 5, 2021 | Nektar Therapeutics, University of Wisconsin |
| NCT04730349 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2021 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT04209114 | Phase 3 | Jan 15, 2020 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT03835533 | Phase 1 | Jun 30, 2019 | Bristol-Myers Squibb, Cancer Research Institute, Celldex Therapeutics, Inovio Pharmaceuticals, Oncovir, Inc., The Parker Institute |
| NCT03772288 | Phase 1 | Apr 3, 2019 | Millennium Pharmaceuticals, Nektar Therapeutics |
| NCT03745807 | Phase 1 | Feb 12, 2019 | Bristol-Myers Squibb, Nektar Therapeutics, Ono Pharmaceuticals |
| NCT03635983 | Phase 3 | Sep 14, 2018 | Bristol-Myers Squibb, Nektar Therapeutics |
| NCT03282344 | Phase 2 | Sep 12, 2017 | Memorial Sloan-Kettering Cancer Center, University of Texas at Houston |
| NCT03138889 | Phase 1 | Jun 9, 2017 | Nektar Therapeutics |
| NCT02983045 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Nektar Therapeutics |
| NCT02869295 | Phase 1 | Dec 1, 2015 | Nektar Therapeutics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nektar Therapeutics | For profit | 9 | 3 | 3 | 2015 |
| Bristol-Myers Squibb | For profit | 5 | 4 | 3 | 2018 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Celldex Therapeutics | For profit | 1 | 0 | 1 | 2019 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Millennium Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2019 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2019 |
| The Parker Institute | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2021 |
12 organizations
Page 1 / 1